05.01.07
Next Pharmaceuticals has revealed the results of a clinical study on its new patented ingredient Citrofen. Results indicate that the new patented formulation cuts stiffness in half for participants who had knee osteoarthritis and it boosted comfort and mobility by up to 50%. These results were obtained in a double-blind, placebo-controlled clinical trial with 80 overweight and normal weight subjects. The clinical trial concluded that Citrofen has multiple benefits in people with knee osteoarthritis, including significant loss of weight.
Citrofen was developed out of research Next has been conducting on its patented extract from orange peel. This patented extract (U.S. Patent No. 6,184,246) was blended with a proprietary extract of the bark from the Phellodendron tree to arrive at the Citrofen formulation.
For further information: 760-602-4224.
Citrofen was developed out of research Next has been conducting on its patented extract from orange peel. This patented extract (U.S. Patent No. 6,184,246) was blended with a proprietary extract of the bark from the Phellodendron tree to arrive at the Citrofen formulation.
For further information: 760-602-4224.